Weight loss during telaprevir-based triple therapy due to telaprevir-induced appetite loss.


OBJECTIVE The sustained virological response (SVR) rate has improved to >70% for patients with hepatitis C virus genotype 1 treated with the triple therapy of telaprevir (TVR), pegylated interferon (PEG-IFN)-α, and ribavirin (RBV). However, this therapy has various adverse effects, although there have been no reports of it decreasing body weight. METHODS… (More)


  • Presentations referencing similar topics